Top Colorectal Cancer Trials to Watch at ESMO 2025
Liquid‑biopsy‑guided ctDNA can refine post‑surgical adjuvant therapy in stage II–III colon cancer, reducing unnecessary toxicity while potentially improving outcomes.
The ESMO 2025 Congress will present data from several early‑phase trials in colorectal cancer, highlighting the potential of liquid‑biopsy‑guided treatment, new immunotherapy combinations, and targeted agents to shape future standards of care.
If validated, ctDNA‑guided adjuvant therapy could spare low‑risk patients from overtreatment and spare high‑risk patients from relapse, thereby improving survival and quality of life.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics